ABBOTT-CITALOPRAM TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

CITALOPRAM (CITALOPRAM HYDROBROMIDE)

Disponibbli minn:

ABBOTT LABORATORIES, LIMITED

Kodiċi ATC:

N06AB04

INN (Isem Internazzjonali):

CITALOPRAM

Dożaġġ:

40MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

CITALOPRAM (CITALOPRAM HYDROBROMIDE) 40MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0136243002; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2015-12-31

Karatteristiċi tal-prodott

_ _
_Abbott-Citalopram Product Monograph _
_Page 1 of 48_
PRODUCT MONOGRAPH
PR
ABBOTT-CITALOPRAM _ _
Citalopram Tablets USP
10 mg, 20 mg and 40 mg citalopram (as citalopram hydrobromide)
Antidepressant
BGP Pharma Inc.
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Preparation:
January 7, 2015
Submission Control No.: 180716
_ _
_Abbott-Citalopram Product Monograph _
_Page 2 of 48 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
............................................................28
STORAGE AND STABILITY
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL INFORMATION
..........................................................................31
CLINICAL TRIALS
.......................................................................................